Differential Effects of Allopregnanolone on the Escalation of Cocaine Self-administration and Sucrose Intake in Female Rats
Overview
Affiliations
Rationale: Evidence suggests that the progesterone metabolite allopregnanolone (ALLO) decreases cocaine seeking in animal models of relapse.
Objective: The purpose of this study was to examine the effects of ALLO on an animal model of cocaine and sucrose bingeing (escalation). Allopregnanolone's effects on yohimbine-induced sucrose intake were also examined. In a separate group of animals, dose interactions between ALLO and cocaine were examined with an abbreviated procedure, a short access progressive ratio (PR) schedule for cocaine reinforcement.
Methods: Female rats were treated with ALLO (15 mg/kg, s.c.) or vehicle (VEH) and trained to lever press for cocaine infusions (0.4 mg/kg) under an extended-access procedure. In a separate condition, other ALLO- and VEH-treated female rats self-administered orally delivered liquid sucrose. Allopregnanolone and VEH treatment was then discountinued and the sucrose-maintained rats were administered priming injections of saline, yohimbine, or yohimbine + ALLO. For the PR condition, rats were first treated with VEH until reaching stability at four doses of cocaine (0.2, 0.4, 0.8, and 1.6 mg/kg in mixed order). Subsequently, rats re-established their baseline cocaine intake at the four cocaine doses following treatment with each of two counterbalanced doses of ALLO (15 and 30 mg/kg).
Results: ALLO significantly blocked the escalation of cocaine self-administration but did not reliably affect intake of sucrose under a similar condition or affect cocaine intake at several doses under a PR schedule. Yohimbine significantly increased sucrose intake while ALLO failed to attenuate this increase.
Conclusion: These findings indicate that ALLO protects against binge-like patterns of cocaine intake but does not reduce sugar intake that is acutely increased by yohimbine in females.
Boero G, McFarland M, Tyler R, OBuckley T, Chery S, Robinson D Biomolecules. 2023; 13(8).
PMID: 37627270 PMC: 10452864. DOI: 10.3390/biom13081205.
Milivojevic V, Charron L, Fogelman N, Hermes G, Sinha R Biomolecules. 2022; 12(11).
PMID: 36358943 PMC: 9687893. DOI: 10.3390/biom12111593.
Beasley M, Gunawan T, Tunstall B, Kearns D Learn Behav. 2022; 50(4):509-523.
PMID: 35132517 PMC: 10237344. DOI: 10.3758/s13420-022-00512-w.
Marusich J, Gay E, Watson S, Blough B Eur J Pharmacol. 2021; 897:173935.
PMID: 33577836 PMC: 7965342. DOI: 10.1016/j.ejphar.2021.173935.
Allen S, Harrison K, Petersen A, Goodson J BMC Res Notes. 2019; 12(1):473.
PMID: 31370907 PMC: 6669967. DOI: 10.1186/s13104-019-4503-x.